10-Q: Summit Therapeutics Q3 Loss Widens Amid R&D Surge

Summit Therapeutics reported a significantly wider net loss in Q3 2025, driven by increased R&D and administrative expenses, despite positive clinical trial updates for ivonescimab.

Summary

• Net loss for the nine months ended September 30, 2025, significantly increased to $860.4 million, compared to $160.1 million for the same period in 2024.
• Research and development expenses surged to $390.4 million for the nine months ended September 30, 2025, up from $99.4 million in the prior year, primarily due to ivonescimab development and a $161.5 million increase in stock-based compensation.
• General and administrative expenses also rose substantially to $479.1 million for the nine months ended September 30, 2025, from $46.0 million in 2024, largely driven by a $419.2 million increase in stock-based compensation due to a modification of performance-based stock option awards.
• Cash used in operating activities for the nine months ended September 30, 2025, was $221.0 million, compared to $93.4 million in the prior year.
• As of September 30, 2025, cash and cash equivalents stood at $238.6 million, with an accumulated deficit of $2.075 billion.
• The company's cash and cash equivalents are not sufficient to fund planned operations for at least one year, raising substantial doubt about its ability to continue as a going concern.
• The HARMONi Phase III study for ivonescimab in 2L+ EGFRm NSCLC demonstrated a statistically significant improvement in progression-free survival (PFS) with a hazard ratio of 0.52 (p<0.00001).
• An additional analysis of HARMONi in September 2025 showed an improved nominal p-value for overall survival (OS) in western patients (HR=0.78; nominal p=0.0332), with median OS of 17.0 months for ivonescimab vs. 14.0 months for placebo in western patients.
• The company plans to submit a Biologics License Application (BLA) for ivonescimab plus chemotherapy in 2L+ EGFRm NSCLC in Q4 2025, despite the FDA noting that a statistically significant OS benefit is necessary for marketing authorization in this setting.
• A protocol amendment for the HARMONi-3 study (1L metastatic NSCLC) was announced in October 2025 to separate statistical analysis by histology, potentially leading to different timelines for results.
• The company intends to start HARMONi-GI3, a Phase III trial for ivonescimab in 1L unresectable metastatic colorectal cancer (CRC), with sites activating in the US before year-end.

Sentiment

Score: 4

Explanation: While the clinical data for ivonescimab, particularly the HARMONi PFS results and improved OS trend in western patients, are positive and Akeso's approvals in China are encouraging, the company faces severe financial challenges. The substantial increase in net loss, cash burn, and the explicit 'going concern' warning, coupled with the need for significant future capital raises and ongoing legal/patent challenges, indicate a high level of financial risk. The positive clinical developments are overshadowed by the immediate and pressing liquidity concerns.

Positives

• Ivonescimab's HARMONi Phase III study achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS) (HR 0.52, p<0.00001) in 2L+ EGFRm NSCLC.
• Longer-term follow-up analysis of HARMONi showed an improved nominal p-value for overall survival (OS) in western patients (HR=0.78; nominal p=0.0332), with median OS of 17.0 months for ivonescimab vs. 14.0 months for placebo in western patients.
• The safety profile of ivonescimab in HARMONi was acceptable and manageable in the context of observed clinical benefit.
• Akeso, the collaboration partner, received approval for ivonescimab in China for 2L+ EGFRm NSCLC (HARMONi-A) and 1L PD-L1 positive NSCLC monotherapy (HARMONi-2), with HARMONi-A demonstrating statistically significant OS benefit in its final analysis.
• The company expanded its licensed territories for ivonescimab to include Latin America, Middle East, and Africa regions.
• The at-the-market (ATM) offering capacity was increased by an additional $360 million, providing a potential source of future funding.

Negatives

• Reported a significantly wider net loss of $860.4 million for the nine months ended September 30, 2025, compared to $160.1 million in the prior year.
• Cash used in operating activities more than doubled to $221.0 million for the nine months ended September 30, 2025, from $93.4 million in the prior year.
• Accumulated deficit increased to $2.075 billion as of September 30, 2025.
• The company's cash and cash equivalents are not sufficient to fund planned operations for at least one year, raising substantial doubt about its ability to continue as a going concern.
• The FDA has indicated that a statistically significant overall survival benefit is necessary to support marketing authorization for ivonescimab in the 2L+ EGFRm NSCLC setting, which was not achieved in the primary analysis of HARMONi.
• Significant increases in research and development ($291.0 million increase) and general and administrative expenses ($433.1 million increase) for the nine months ended September 30, 2025, largely due to a $620.6 million increase in stock-based compensation from a modification of performance-based stock option awards.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient cash to fund operations for the next twelve months.
• The company will need to raise significant additional capital through equity, debt, or collaborations, and there is no assurance that such financing will be available on acceptable terms or at all.
• The Biologics License Application (BLA) for ivonescimab in 2L+ EGFRm NSCLC may not receive marketing authorization if regulatory authorities, such as the FDA, determine that additional trials or data, particularly a statistically significant overall survival benefit, are necessary.
• An unknown third party filed a notice of opposition against the company's in-licensed EP3882275B1 patent covering ivonescimab in Europe, asserting a lack of inventive step, which could impact intellectual property rights.
• A derivative lawsuit was filed against certain current and former directors and the company concerning the December 2022 Promissory Notes, asserting claims for breach of fiduciary duty and unjust enrichment, seeking unspecified damages and rescission of shares.
• Future capital requirements are substantial, including potential milestone payments of up to $4.56 billion to Akeso and low double-digit royalties on net sales, which the company may struggle to meet without additional funding.
• Clinical trial outcomes for ivonescimab in ongoing and planned studies (HARMONi-3, HARMONi-7, HARMONi-GI3) are uncertain and may not yield positive results or regulatory approvals.
• The company relies on third parties, including Akeso, for drug substance and product supply, and any disruptions could adversely affect development and commercialization.

Future Outlook

The company plans to submit a Biologics License Application (BLA) for ivonescimab plus chemotherapy in 2L+ EGFRm NSCLC in the fourth quarter of 2025. It intends to expand ivonescimab's clinical development program with additional Phase III studies, including initiating HARMONi-GI3 for colorectal cancer before year-end. Enrollment in the HARMONi-3 squamous cohort is expected to complete in H1 2026, with PFS analysis in H2 2026, while the non-squamous cohort enrollment is expected to complete in H2 2026, with PFS analysis in H1 2027. The company expects to continue generating operating losses and will need to raise additional capital to fund ongoing operations and capital needs, including potential milestone payments to Akeso.

Management Comments

• Management believes the safety and efficacy data generated in the HARMONi study demonstrates that patients suffering from EGFR-mutant NSCLC in this setting can benefit from the ivonescimab regimen, despite the lack of a statistically significant showing on overall survival in the primary analysis.
• Management expects oncology-related research and development costs to continue to increase as the company progresses with the development of ivonescimab.
• Management expects general and administrative expenses to continue to increase as the company scales its infrastructure and management to support the development of ivonescimab.

Industry Context

Ivonescimab is positioned as a novel, potential first-in-class PD-1 / VEGF bispecific antibody, aiming to combine immunotherapy and anti-angiogenesis effects into a single molecule. Its unique cooperative binding mechanism and tetravalent structure are designed to enhance antitumor activity and potentially improve upon established efficacy and safety profiles compared to existing combination therapies. The development in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) places it in highly competitive oncology markets, where current standards of care include therapies like pembrolizumab and bevacizumab. The FDA's emphasis on statistically significant overall survival for marketing authorization in 2L+ EGFRm NSCLC highlights the high bar for new treatments in this space.

Comparison to Industry Standards

• In the HARMONi-3 study, ivonescimab plus platinum-based doublet chemotherapy is being compared directly against pembrolizumab plus platinum-based doublet chemotherapy in first-line metastatic NSCLC, indicating a direct competition with a leading PD-1 inhibitor.
• The HARMONi-7 study compares ivonescimab monotherapy to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression, directly benchmarking against a current standard of care.
• The planned HARMONi-GI3 study will evaluate ivonescimab plus chemotherapy against bevacizumab plus chemotherapy as first-line therapy in unresectable metastatic colorectal cancer, positioning ivonescimab against another established anti-angiogenesis agent.
• The FDA's requirement for a statistically significant overall survival benefit for marketing authorization in 2L+ EGFRm NSCLC sets a high industry benchmark that ivonescimab's primary HARMONi analysis did not meet, although subsequent analysis showed an improved nominal p-value for OS in western patients.

Corporate Governance

Legal Proceedings

• A derivative lawsuit was filed on March 17, 2025, by Rainaldi Revocable Trust against certain current and former directors and the company, concerning the December 2022 Promissory Notes. Claims include breach of fiduciary duty and unjust enrichment, seeking unspecified damages and rescission of shares. The motion to dismiss and motion to certify constitutional questions are currently stayed.
• An unknown third party filed a notice of opposition on June 18, 2025, against the company's in-licensed EP3882275B1 patent (covering ivonescimab) in the European Opposition Division of the European Patent Office, primarily asserting a lack of inventive step. The company intends to contest these assertions.

Related Party Transactions

• Promissory notes totaling $520 million were issued to Co-CEO Robert W. Duggan and Co-CEO Dr. Mahkam Zanganeh in December 2022, which were fully repaid by October 1, 2024.
• In the September 2024 Private Placement, Section 16 officers (Robert W. Duggan, Dr. Mahkam Zanganeh, Manmeet S. Soni, and Jeff Huber via a controlled entity) collectively purchased $78.5 million in common stock. Mr. Duggan's $75.5 million purchase was used to repay a portion of his promissory note.
• Co-CEO Robert W. Duggan exercised 3,985,055 warrants in March and April 2025 at an exercise price of $1.58 per share.
• The company has sublease agreements with Maky Zanganeh and Associates, Inc. (MZA), an entity owned by Co-CEO Dr. Maky Zanganeh, for office space in Menlo Park, California, with payments of $207k and $621k for the three and nine months ended September 30, 2025, respectively.
• The company entered into sublease agreements for its Miami headquarters with Genius 24C Inc. and Duggan Investments Research LLC, both affiliates of Co-CEO Robert W. Duggan, recognizing sublease income of $46k and $140k for the three and nine months ended September 30, 2025, respectively.
• The company incurred expenses of approximately $0.7 million and $1.4 million for legal services rendered by Wilson Sonsini Goodrich & Rosati P.C. (WSGR) for the three and nine months ended September 30, 2025, respectively, where Board member Kenneth A. Clark is a partner.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and potential future equity capital raises, as well as the uncertainty associated with the 'going concern' warning and legal proceedings.
• Employees benefit from substantial stock-based compensation, particularly due to the modification of performance-based options, which may aid in retention but also contributes to the company's high operating expenses.
• Akeso, as a collaboration partner, stands to receive substantial future milestone payments (up to $4.56 billion) and low double-digit royalties if ivonescimab achieves regulatory approvals and commercial success.
• Customers (future patients) could benefit from ivonescimab as a new treatment option, particularly in NSCLC and potentially CRC, if regulatory approvals are secured.
• Creditors face increased risk due to the company's 'going concern' warning and substantial accumulated deficit, although existing promissory notes to related parties have been repaid.

Next Steps

• Submit a Biologics License Application (BLA) for ivonescimab plus chemotherapy in 2L+ EGFRm NSCLC in the fourth quarter of 2025.
• Continue enrollment in the HARMONi-3 study for 1L metastatic NSCLC, with separate analyses planned for squamous and non-squamous cohorts.
• Continue enrollment in the HARMONi-7 study for 1L metastatic NSCLC with high PD-L1 expression.
• Initiate the HARMONi-GI3 Phase III clinical trial for ivonescimab in 1L unresectable metastatic colorectal cancer (CRC) with US sites activating before year-end.
• Explore further clinical development of ivonescimab in solid tumor settings outside of current focus areas through investigator-sponsored trials.
• Actively pursue additional financing through equity and debt offerings, collaborations, and other arrangements to address liquidity concerns and fund ongoing operations.
• Respond to the European Patent Opposition against the ivonescimab patent.

Key Dates

Recommendation

While the clinical data for ivonescimab, particularly the statistically significant PFS benefit in HARMONi and the improved OS trend in western patients, represents a significant positive for the company's pipeline, the severe financial challenges cannot be overlooked. The substantial increase in net loss, cash burn, and the explicit 'going concern' warning indicate a high level of financial risk and uncertainty regarding the company's ability to fund its operations for the next 12 months. The need for significant future capital raises, which will likely result in further shareholder dilution, and ongoing legal/patent challenges, create considerable headwinds. An investor should 'hold' to monitor the BLA submission outcome and the company's ability to secure necessary financing, but with extreme caution given the fundamental liquidity issues.

Keywords

Biopharmaceutical, Oncology, Ivonescimab, NSCLC, Colorectal Cancer, Clinical Trials, Phase III, SEC Filing, 10-Q, Summit Therapeutics, Akeso, PD-1, VEGF, Bispecific Antibody, Going Concern, Capital Raise